MGNX

SEC source: 0001125345-22-000066 · wf-form4_165335442559623.xml · derivative · entry 2

O'Brien Federica F. · CIK 0001140119 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,080

Underlying: Common Stock · 24,080 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

F2 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000066 · wf-form4_165335442559623.xml · derivative · entry 1

O'Brien Federica F. · CIK 0001140119 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000067 · wf-form4_165335444265450.xml · derivative · entry 2

SIEGEL JAY PHILIP · CIK 0001722857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,080

Underlying: Common Stock · 24,080 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

F2 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000067 · wf-form4_165335444265450.xml · derivative · entry 1

SIEGEL JAY PHILIP · CIK 0001722857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000065 · wf-form4_165335440496083.xml · derivative · entry 1

Jackson Scott Thomas · CIK 0001566617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000063 · wf-form4_165335437160079.xml · derivative · entry 2

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,640

Underlying: Common Stock · 20,640 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

F2 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000063 · wf-form4_165335437160079.xml · derivative · entry 1

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000064 · wf-form4_165335438800176.xml · derivative · entry 1

HURWITZ EDWARD · CIK 0001211840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000049 · wf-form4_165282239043395.xml · derivative · entry 2

Koenig Scott · CIK 0001587514 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 53,265 shares

Expires 2023-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000049 · wf-form4_165282239043395.xml · nonDerivative · entry 1

Koenig Scott · CIK 0001587514 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,049,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse.

SEC source: 0001125345-22-000051 · wf-form4_165282278330600.xml · derivative · entry 3

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which vested on May 14, 2022. Restricted stock units convert into the Company's common stock on a one-for-one basis

F1 · derivative.exercise_date: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which vested on May 14, 2022. Restricted stock units convert into the Company's common stock on a one-for-one basis

F1 · derivative.expiration_date: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which vested on May 14, 2022. Restricted stock units convert into the Company's common stock on a one-for-one basis

SEC source: 0001125345-22-000051 · wf-form4_165282278330600.xml · nonDerivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,424

SEC source: 0001125345-22-000051 · wf-form4_165282278330600.xml · nonDerivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which vested on May 14, 2022. Restricted stock units convert into the Company's common stock on a one-for-one basis

SEC source: 0001125345-22-000036 · wf-form4_164850098330466.xml · derivative · entry 2

Karrels James · CIK 0001587477 · SVP, CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,316 shares

Expires 2023-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000036 · wf-form4_164850098330466.xml · nonDerivative · entry 1

Karrels James · CIK 0001587477 · SVP, CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse.

SEC source: 0001125345-22-000034 · wf-form4_164643390419387.xml · derivative · entry 2

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500 shares

Expires 2022-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000034 · wf-form4_164643390419387.xml · nonDerivative · entry 1

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001125345-22-000028 · wf-form4_164575002906302.xml · derivative · entry 1

Karrels James · CIK 0001587477 · SVP, CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000032 · wf-form4_164575011929211.xml · derivative · entry 1

Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000030 · wf-form4_164575007381460.xml · derivative · entry 2

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant.

F3 · derivative.expiration_date: The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant.

SEC source: 0001125345-22-000030 · wf-form4_164575007381460.xml · derivative · entry 1

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000031 · wf-form4_164575009827558.xml · derivative · entry 1

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000026 · wf-form4_164574998533509.xml · derivative · entry 1

Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,400

Underlying: Common Stock · 63,400 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000029 · wf-form4_164575004704334.xml · derivative · entry 1

Koenig Scott · CIK 0001587514 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,000

Underlying: Common Stock · 480,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000027 · wf-form4_164575000344606.xml · derivative · entry 1

Eck Stephen L. · CIK 0001669041 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000025 · wf-form4_164574996410940.xml · derivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant.

F3 · derivative.expiration_date: The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant.

SEC source: 0001125345-22-000025 · wf-form4_164574996410940.xml · derivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0000899243-21-045703 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,275,564

SEC source: 0001125345-21-000117 · wf-form4_163710182184861.xml · derivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,540 shares

Expires 2023-10-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable on the date reflected and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-21-000117 · wf-form4_163710182184861.xml · nonDerivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-038368 · doc4.xml · nonDerivative · entry 2

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,075,564

SEC source: 0000899243-21-038368 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,975,564

SEC source: 0000899243-21-036543 · doc4.xml · nonDerivative · entry 2

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,875,564

SEC source: 0000899243-21-036543 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,675,564

SEC source: 0001125345-21-000092 · wf-form4_162681532070844.xml · derivative · entry 3

Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,147

Underlying: Common Stock · 5,000 shares

Expires 2023-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-21-000092 · wf-form4_162681532070844.xml · nonDerivative · entry 2

Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.04. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001125345-21-000092 · wf-form4_162681532070844.xml · nonDerivative · entry 1

Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001125345-21-000089 · wf-form4_162492566930067.xml · derivative · entry 4

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,279

Underlying: Common Stock · 4,221 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001125345-21-000089 · wf-form4_162492566930067.xml · derivative · entry 3

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,540

Underlying: Common Stock · 21,855 shares

Expires 2023-10-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable on the date reflected and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-21-000089 · wf-form4_162492566930067.xml · nonDerivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001125345-21-000089 · wf-form4_162492566930067.xml · nonDerivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-025485 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,275,564

SEC source: 0000899243-21-024412 · doc4.xml · nonDerivative · entry 2

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,200,564

SEC source: 0000899243-21-024412 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,100,564

SEC source: 0001125345-21-000084 · wf-form4_162137192693194.xml · derivative · entry 3

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which will vest on May 14, 2022, subject to the reporting person's continued employment with the Company. Restricted stock units convert into the Company's common stock on a one-for-one basis.

F1 · derivative.exercise_date: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which will vest on May 14, 2022, subject to the reporting person's continued employment with the Company. Restricted stock units convert into the Company's common stock on a one-for-one basis.

F1 · derivative.expiration_date: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which will vest on May 14, 2022, subject to the reporting person's continued employment with the Company. Restricted stock units convert into the Company's common stock on a one-for-one basis.

SEC source: 0001125345-21-000084 · wf-form4_162137192693194.xml · nonDerivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,474

SEC source: 0001125345-21-000084 · wf-form4_162137192693194.xml · nonDerivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On May 14, 2020, the reporting person was granted 10,000 restricted stock units, 50% of which vested on May 14, 2021 and 50% of which will vest on May 14, 2022, subject to the reporting person's continued employment with the Company. Restricted stock units convert into the Company's common stock on a one-for-one basis.

SEC source: 0001125345-21-000076 · wf-form4_162130139081001.xml · derivative · entry 1

STUMP DAVID C · CIK 0001191235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-13

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-21-000074 · wf-form4_162130130131615.xml · derivative · entry 1

Jackson Scott Thomas · CIK 0001566617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-13

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-21-000075 · wf-form4_162130135618092.xml · derivative · entry 1

SIEGEL JAY PHILIP · CIK 0001722857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-13

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.